Pancreatic cancer is one of the most aggressive and hard-to-treat cancers, with a five-year survival rate below 20%. Often diagnosed at a late stage, pancreatic cancer poses a challenge in treatment; however, advancements in precision medicine have created new opportunities for more effective and targeted treatments. Today, it is more common for pancreatic cancer patients to get treatment based on their tumor’s biology or their genetic makeup. PanCAN's Know Your Tumor® service provides you and your healthcare team with information about your tumor's biology through free tissue biomarker testing and genetic testing for inherited mutations.
Learn more about precision medicine and how you can benefit. In this blog, PanCAN Chief Science Officer, Lynn Matrisian, PhD, MBA, and Chief Scientific and Medical Officer, Anna Berkenblit, MD, MMSc, express optimism that a new wave of precision medicine breakthroughs may bring progress to pancreatic cancer that other types of cancer have seen over the past several decades.